List of Excipients in Branded Drug ZOHYDRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	AMMONIO METHACRYLATE COPOLYMER TYPE B
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	FD&C BLUE NO. 1
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	FD&C RED NO. 3
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	FD&C RED NO. 40
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	FERRIC OXIDE RED
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	FERRIC OXIDE YELLOW
Zogenix Inc	ZOHYDRO	hydrocodone bitartrate	43376-210	FERROSOFERRIC OXIDE

Zohydro Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Zohydro ER is an extended-release hydrocodone bitartrate product whose commercial value depends on controlled release, abuse-deterrent performance, regulatory compliance, and reliable supply of functional excipients. The strongest opportunity is not a conventional filler substitution. It is the development or supply of excipients that maintain hydrocodone release after crushing, chewing, dissolution, or solvent manipulation while preserving oral bioavailability and manufacturing throughput.

Zohydro ER was approved by the FDA in 2013 under NDA 202880. The original product did not have abuse-deterrent labeling. A reformulated version using the BeadTek technology was approved in 2015 and received abuse-deterrent labeling based on laboratory manipulation studies.[1][2]

What is Zohydro ER and why do excipients matter?

Zohydro ER is an oral extended-release capsule containing hydrocodone bitartrate as the active pharmaceutical ingredient. It was developed for the management of pain severe enough to require a daily, around-the-clock opioid analgesic when alternative treatments are inadequate.[1]

The excipient system has four commercial functions:

1. It controls hydrocodone release over the intended dosing interval.
2. It maintains capsule and bead integrity during storage and handling.
3. It limits hydrocodone extraction after mechanical or chemical manipulation.
4. It supports scalable manufacture, encapsulation, dissolution testing, and batch-to-batch consistency.

The product is therefore a multiparticulate drug-delivery system rather than a simple immediate-release capsule. Excipient choices affect drug loading, release kinetics, dose proportionality, abuse-deterrent performance, food effects, and bioequivalence.

What excipients are used in Zohydro ER?

Public labeling identifies a multiparticulate formulation with inactive ingredients used in the drug-loaded beads, functional coatings, and capsule shell.[1] The excipient categories are more commercially relevant than any single conventional diluent.

Drug-layering excipients

Drug-layering excipients support the deposition of hydrocodone bitartrate onto starter particles. Typical functions include:

• Inert cores or sugar spheres
• Binding polymers
• Wetting agents
• Processing aids
• Coating substrates

The main commercial issue is uniform drug distribution across beads. Poor layering can create dose variability, increase the risk of dose dumping, and complicate content-uniformity testing at higher strengths.

Release-controlling polymers

Extended release generally depends on polymeric barriers that regulate water ingress and hydrocodone diffusion. Relevant polymer classes include:

• Ethylcellulose
• Hypromellose
• Acrylic or methacrylic copolymers
• Other water-permeable or pH-responsive coating polymers

A release-controlling coating must remain functional across the gastrointestinal tract. It also has to withstand capsule filling, shipping, and routine handling without generating excessive fines or damaged beads.

Plasticizers and coating aids

Plasticizers improve film flexibility and reduce cracking during coating and storage. Dibutyl sebacate and related plasticizers are commercially relevant to multiparticulate coating systems, although the precise commercial opportunity depends on the approved formulation and current manufacturing process.

Coating aids can improve:

• Spray efficiency
• Film coalescence
• Coating uniformity
• Mechanical resistance
• Process yield

Suppliers with validated opioid-product excipient grades have an advantage because formulation changes can trigger new extractables, leachables, stability, and bioequivalence work.

Capsule-shell excipients

The capsule shell typically uses gelatin, colorants, opacifiers, and other shell-processing ingredients. These materials are less differentiated than the functional bead system, but they remain subject to pharmaceutical-grade documentation, microbiological controls, traceability, and supply continuity.

How does BeadTek change the excipient opportunity?

BeadTek changes the economic value of the excipient system because the product must address abuse by manipulation, not only release over time. The relevant formulation objective is resistance to common abuse routes, including:

• Crushing and chewing
• Dissolution in water
• Extraction with alcohol or other solvents
• Attempts to separate hydrocodone from the bead matrix

The FDA’s abuse-deterrent labeling guidance evaluates product performance under defined laboratory manipulation conditions. A formulation does not prevent opioid abuse, and laboratory resistance does not establish complete clinical abuse prevention.[3]

For excipient suppliers, the commercial requirement is a measurable performance package:

Performance attribute	Commercial relevance
Crush resistance	Reduces formation of readily injectable or snortable powder
Gel formation or viscosity increase	Limits syringeability and filtration
Reduced extraction	Makes hydrocodone recovery more difficult
Controlled dissolution	Preserves extended release after ordinary oral administration
Low friability	Protects coating integrity during manufacturing and transport
Dose proportionality	Supports multiple capsule strengths
Manufacturability	Determines cost and supply reliability

The most valuable excipient technologies are those that provide manipulation resistance without materially reducing oral exposure or increasing gastrointestinal adverse effects.

What formulation patents protect Zohydro-related technology?

Zohydro-related intellectual-property protection can involve several layers:

• Hydrocodone extended-release compositions
• Multiparticulate bead structures
• Abuse-deterrent formulations
• Manufacturing processes
• Release profiles
• Methods of treating pain
• Drug-device or packaging elements

Patent protection should be separated from FDA approval. An FDA-approved product can have patents listed in the Orange Book, while additional formulation or manufacturing patents may not be listed there.[4]

A commercial diligence review should examine:

IP layer	Key diligence question
Composition patents	Do claims cover the bead, polymer, or excipient combination?
Process patents	Is the coating or layering process claimed?
Abuse-deterrence patents	Are resistance properties tied to a specific material or structure?
Method-of-use patents	Do claims cover dosing or treatment of a defined pain population?
Supplier rights	Is the excipient technology licensed, internally owned, or contract-manufactured?
Geographic scope	Are equivalent rights active in the United States, Europe, Canada, and other target markets?

The strongest patent position typically claims a defined formulation architecture and measurable performance, rather than a broad reference to an excipient class. A generic that substitutes one polymer for another may still face infringement risk if the claims cover the resulting release profile, bead structure, or abuse-deterrent mechanism.

When does Zohydro lose exclusivity?

Zohydro’s commercial exclusivity is governed by several different dates:

• FDA regulatory exclusivity
• Listed patent expiration dates
• Pediatric exclusivity, if granted
• Litigation stays arising from Paragraph IV certifications
• Market availability of an approved generic
• Commercial decisions by the product owner

Zohydro ER received five-year new chemical entity exclusivity when approved in 2013, subject to the statutory framework applicable to the NDA.[1] That period did not prevent all later regulatory activity indefinitely. Patent and regulatory barriers are separate.

A generic applicant may submit an ANDA with a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed. The NDA holder can file patent litigation, potentially creating a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.[5]

Because patent listings and litigation outcomes can change, the current generic-entry assessment must use the FDA Orange Book, FDA litigation records, and federal court dockets rather than an old product label.[4]

What is the Orange Book status of Zohydro?

The Orange Book is the principal FDA source for listed patents, therapeutic-equivalence evaluations, and approved drug products.[4] Its relevance to Zohydro includes:

• Identification of the reference listed drug
• Listed patents and expiration dates
• Any approved generic equivalents
• Therapeutic-equivalence codes
• Product discontinuation status

A discontinued product can remain relevant to ANDA strategy if the FDA determines that the reference product was not withdrawn for safety or efficacy reasons. Generic applicants must also evaluate whether the dosage form, release characteristics, and abuse-deterrent labeling create additional regulatory requirements.

What generic-entry risks exist for Zohydro?

Generic development faces a higher technical burden than a conventional immediate-release hydrocodone product.

Bioequivalence and release performance

A generic applicant must match the relevant pharmacokinetic profile. For an extended-release opioid, this may include:

• Cmax
• AUC
• Partial AUC
• Fed and fasting conditions
• Multiple-dose behavior
• Alcohol-interaction testing
• Dose proportionality

The formulation must also avoid dose dumping after alcohol exposure or mechanical manipulation.

Abuse-deterrent equivalence

A generic seeking abuse-deterrent labeling may need to demonstrate comparable abuse-deterrent properties under FDA guidance. A conventional extended-release hydrocodone capsule may not be commercially equivalent in positioning if it lacks the same labeling.

This creates two market paths:

1. A lower-cost generic without abuse-deterrent labeling.
2. A technically differentiated generic that seeks comparable abuse-deterrent claims.

The second path has greater development cost but may support better formulary positioning and lower substitution risk where payers or institutions value abuse-deterrent properties.

Which excipient opportunities are commercially attractive?

Co-processed abuse-deterrent excipients

A supplier could offer a pre-engineered excipient platform that combines matrix formers, viscosity enhancers, and release-controlling polymers. The value proposition is reduced formulation screening and a shorter development cycle.

The platform must be supported by:

• Drug-extraction data
• Crush and tamper testing
• Rheology measurements
• Dissolution profiles
• Stability data
• Regulatory documentation
• Scale-up performance

High-performance coating systems

Multiparticulate opioids require coating systems with narrow process variability. Opportunities include aqueous coatings with improved film strength, lower residual solvent burden, and better resistance to mechanical damage.

A coating supplier can differentiate through:

• Lower coating weight variability
• Reduced curing time
• Improved adhesion
• Lower defect rates
• Compatibility with high-throughput fluid-bed equipment

Solvent-resistant and low-extractability materials

Excipient systems that reduce hydrocodone recovery from water, alcohol, or mixed solvents have direct relevance to abuse-deterrent products. The commercial challenge is balancing extraction resistance with acceptable oral dissolution.

Generic-ready formulation packages

A formulation package containing qualified excipients, process parameters, analytical methods, and reference dissolution data may be more valuable than a raw-material sale. Generic manufacturers could use such packages to reduce development time and analytical risk.

Capsule and packaging systems

Tamper-evident packaging, unit-dose formats, and child-resistant systems are secondary opportunities. They do not replace abuse-deterrent formulation technology, but they can support controlled distribution, institutional use, and compliance programs.

How does Zohydro compare with Hysingla ER and other extended-release opioids?

Product	Active ingredient	Release form	Abuse-deterrent positioning	Excipient opportunity
Zohydro ER	Hydrocodone bitartrate	Multiparticulate extended-release capsule	Reformulated version received abuse-deterrent labeling	Bead coating, extraction resistance, generic formulation
Hysingla ER	Hydrocodone bitartrate	Extended-release tablet	Abuse-deterrent tablet technology	Hard matrix, gelling system, tablet robustness
OxyContin	Oxycodone hydrochloride	Extended-release tablet	Abuse-deterrent formulation	High-viscosity matrix and tablet manipulation resistance
Xtampza ER	Oxycodone	Microsphere-based capsule	Abuse-deterrent formulation	Lipid-based microspheres and food-effect control

Zohydro’s capsule and multiparticulate architecture creates a different supplier opportunity from tablet-based products. Bead coating, capsule filling, and multiparticulate dose uniformity are more important than high-compression tablet technology.

What regulatory barriers affect commercialization?

Zohydro is subject to the regulatory controls applicable to Schedule II opioids. The commercial environment includes:

• FDA requirements for extended-release opioid labeling
• Abuse-deterrent testing expectations
• Opioid Analgesic REMS requirements
• DEA controlled-substance quotas and recordkeeping
• State prescribing restrictions
• Manufacturing security and diversion controls
• Pharmacovigilance obligations
• Post-approval change controls

A new excipient is not automatically interchangeable with an existing pharmaceutical excipient. A formulation change may require a comparability package, stability studies, dissolution bridging, and potentially supplemental FDA filing activity.

For a generic, excipient substitution can affect ANDA risk if it changes release, abuse-deterrent performance, impurity levels, or pharmacokinetics. The lowest-cost excipient is not necessarily the lowest-cost regulatory option.

What is the commercial outlook for Zohydro excipients?

The addressable market is narrower than the broader opioid-excipient market because Zohydro has faced intense prescribing controls, generic competition, declining opioid utilization, and commercial uncertainty. The best opportunities are platform-based rather than dependent on continued sales of one branded product.

Potential customers include:

• Generic opioid manufacturers
• Specialty pharmaceutical companies
• Abuse-deterrent technology licensors
• Contract development and manufacturing organizations
• Excipient manufacturers
• Drug-delivery companies
• Institutional and hospital suppliers

Revenue potential is strongest where an excipient platform can be transferred to several opioid products or non-opioid controlled-release products. A product-specific supply agreement tied only to Zohydro carries higher volume and discontinuation risk.

Key Takeaways

• Zohydro ER is a hydrocodone bitartrate extended-release multiparticulate capsule.
• The principal excipient opportunity is functional performance, not commodity filling material.
• Bead coating, controlled release, crush resistance, and reduced solvent extraction are the highest-value technical areas.
• The BeadTek reformulation increased the importance of abuse-deterrent excipient systems.
• Generic development must address pharmacokinetics, alcohol interaction, dissolution, and potentially abuse-deterrent performance.
• The Orange Book is necessary for current patent, generic, and reference-product status.
• Patent review should cover composition, bead architecture, manufacturing process, method of use, and licensed technology rights.
• Commercial risk is high for a Zohydro-only excipient strategy because opioid prescribing and branded-product economics remain constrained.
• A transferable abuse-deterrent or multiparticulate platform has greater long-term value than a product-specific material.

FAQs

Can conventional ethylcellulose or hypromellose replace Zohydro’s functional excipients?

Not automatically. Substitution can change release kinetics, alcohol sensitivity, extraction behavior, stability, and bioequivalence. Each replacement requires formulation and regulatory evaluation.

Does abuse-deterrent labeling guarantee lower opioid abuse?

No. FDA labeling reflects defined laboratory and clinical evidence categories. It does not establish that a product prevents abuse or diversion.[3]

Is Zohydro a tablet or a capsule?

Zohydro ER is an extended-release capsule containing multiparticulate drug-loaded material.[1]

Can a generic Zohydro product use different excipients?

Yes, subject to applicable ANDA requirements. The generic must demonstrate pharmaceutical equivalence and bioequivalence and may need to address differences affecting abuse-deterrent performance or labeling.

Are Zohydro excipient patents the same as hydrocodone patents?

No. Hydrocodone API patents, extended-release formulation patents, abuse-deterrent patents, manufacturing patents, and method-of-use patents are distinct rights and must be analyzed separately.

References

1. U.S. Food and Drug Administration. (2013). Zohydro ER prescribing information, NDA 202880. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202880s000lbl.pdf

2. Zogenix, Inc. (2015). Zogenix announces FDA approval of reformulated Zohydro ER with BeadTek. https://ir.zogenix.com/

3. U.S. Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. https://www.fda.gov/media/84819/download

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments-and-abbreviated-new-drug-applications-anda-filing-and-review-process